Sacituzumab tirumotecan · TroFuse-009
Merck lists this exact NCT in the lung-cancer program. It is TroFuse-009 after EGFR-TKI progression, not the positive endometrial TroFuse-005 readout or Chinese OptiTROP results. sacituzumab tirumotecan — phase 3 study in Non-small Cell Lung Cancer (NSCLC). NCT06305754 lists Overall Survival (OS) as a primary outcome (Up to approximately 51 months). Registry status: active not recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- Primary completion is not a guaranteed topline publication or regulatory decision date.
- Registry primary completion: 2028-08-17 (estimated); verify independently before using it as a catalyst date.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
Primary evidence
Phase 3 lung-cancer monitor — date unconfirmed
Potential outcome market
Will sacituzumab tirumotecan meet the prespecified primary endpoint in NCT06305754 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.